Cargando…

The emerging landscape of EFGR tyrosine kinase inhibitors in lung adenocarcinoma—successes and challenges

Detalles Bibliográficos
Autores principales:	Oduah, Eziafa I., Lee, Chung-Shien, Seetharamu, Nagarashee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264087/ https://www.ncbi.nlm.nih.gov/pubmed/35813761 http://dx.doi.org/10.21037/jtd-22-432

Ejemplares similares

Complete Genome Sequences of Two Enterococcus faecalis Bacteriophages, EFGrKN and EFGrNG, Targeted to Phage Therapy
por: Alkalay-Oren, Sivan, et al.
Publicado: (2021)

Harnessing the vulnerabilities of p53 mutants in lung cancer – Focusing on the proteasome: a new trick for an old foe?
por: Oduah, Eziafa I., et al.
Publicado: (2020)

A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity
por: Lee, Chung-Shien, et al.
Publicado: (2020)

Heparin: Past, Present, and Future
por: Oduah, Eziafa I., et al.
Publicado: (2016)

Ketogenic Diet-Induced Severe Ketoacidosis in a Lactating Woman: A Case Report and Review of the Literature
por: Nnodum, Benedicta Nneoma, et al.
Publicado: (2019)

Osimertinib in EGFR-Mutated Lung Cancer: A Review of the Existing and Emerging Clinical Data
por: Lee, Chung-Shien, et al.
Publicado: (2021)

Single-Droplet Microsensor for Ultra-Short Circulating EFGR Mutation Detection in Lung Cancer Based on Multiplex EFIRM Liquid Biopsy
por: Wei, Fang, et al.
Publicado: (2023)

The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib
por: Wilding, Christopher P, et al.
Publicado: (2019)

A cuproptosis-related long non-coding RNA signature to predict the prognosis and immune microenvironment characterization for lung adenocarcinoma
por: Ma, Shouzheng, et al.
Publicado: (2022)

Pretreatment nutritional status and response to checkpoint inhibitors in lung cancer
por: Lee, Chung-Shien, et al.
Publicado: (2020)

Uncommon EGFR mutations in lung adenocarcinoma: features and response to tyrosine kinase inhibitors
por: Brindel, Aurélien, et al.
Publicado: (2020)

Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications
por: Quintanal-Villalonga, A., et al.
Publicado: (2016)

Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
por: Pottier, Charles, et al.
Publicado: (2020)

The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
por: Wu, Shang-Gin, et al.
Publicado: (2016)

Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC
por: Nelson, Valerie, et al.
Publicado: (2013)

Profile of Capmatinib for the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC): Patient Selection and Perspectives
por: Fraser, Madison, et al.
Publicado: (2023)

Corrigendum to “Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications”
por: Quintanal-Villalonga, A., et al.
Publicado: (2018)

Receptor Tyrosine Kinases and Inhibitors in Lung Cancer
por: Pisick, Evan, et al.
Publicado: (2004)

Challenges Associated with Tyrosine Kinase Inhibitor Therapy for Metastatic Thyroid Cancer
por: Cabanillas, Maria E., et al.
Publicado: (2011)

Tyrosine Kinase Inhibitors for Glioblastoma Multiforme: Challenges and Opportunities for Drug Delivery
por: Brar, Harpinder K., et al.
Publicado: (2022)

Current progress and open challenges for applying tyrosine kinase inhibitors in osteosarcoma
por: Chen, Chenglong, et al.
Publicado: (2022)

Epidemiology and clinicopathological features of lung cancer in patients with prior history of breast cancer
por: Wang, Kevin Y, et al.
Publicado: (2021)

Different mutational characteristics of the subsets of EGFR-tyrosine kinase inhibitor sensitizing mutation-positive lung adenocarcinoma
por: Kim, Eun Young, et al.
Publicado: (2018)

MUSASHI‐2 confers resistance to third‐generation EGFR‐tyrosine kinase inhibitor osimertinib in lung adenocarcinoma
por: Yiming, Reheman, et al.
Publicado: (2021)

Targeting GSTP1 as Therapeutic Strategy against Lung Adenocarcinoma Stemness and Resistance to Tyrosine Kinase Inhibitors
por: Wang, Si‐Qi, et al.
Publicado: (2023)

Tyrosine Kinase Inhibitors and Interferon
por: Dimou, Maria, et al.
Publicado: (2014)

Tyrosine Kinase Inhibitors for the Elderly
por: Hohenforst-Schmidt, Wolfgang, et al.
Publicado: (2016)

Tyrosine Kinase Inhibitors and Pregnancy
por: Abruzzese, Elisabetta, et al.
Publicado: (2014)

Nanomedicine of tyrosine kinase inhibitors
por: Smidova, Veronika, et al.
Publicado: (2021)

Resistance to the tyrosine kinase inhibitor axitinib is associated with increased glucose metabolism in pancreatic adenocarcinoma
por: Hudson, C D, et al.
Publicado: (2014)

Association of smoking and ALK tyrosine-kinase inhibitors on overall survival in treatment-naïve ALK-positive advanced lung adenocarcinoma
por: Zheng, Zhe-Rong, et al.
Publicado: (2023)

Efficacy and Failure Patterns of Early SBRT to the Primary Tumor in Advanced EGFR-Mutation-Positive Lung Cancer with EFGR-TKI Treatment: A Prospective, Single Arm, Phase II Study
por: Shi, Yangyang, et al.
Publicado: (2022)

Association of EGFR Tyrosine Kinase Inhibitor Treatment With Progression-Free Survival Among Taiwanese Patients With Advanced Lung Adenocarcinoma and EGFR Mutation
por: Chen, Po-Yen, et al.
Publicado: (2021)

Predictive indicators of successful tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia
por: Stuckey, Ruth, et al.
Publicado: (2020)

Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success
por: Inzoli, Elena, et al.
Publicado: (2022)

A new receptor tyrosine kinase inhibitor, icotinib, for patients with lung adenocarcinoma cancer without indication for chemotherapy
por: ZHENG, XIAO, et al.
Publicado: (2014)

Subsequent treatment of epidermal growth factor receptor-tyrosine kinase inhibitor failure in patients with advanced lung adenocarcinoma
por: Qiao, Xiaojuan, et al.
Publicado: (2015)

Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung Adenocarcinoma
por: Chang, Yoon Soo, et al.
Publicado: (2016)

EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors
por: Yang, Jiyoul, et al.
Publicado: (2018)

Tyrosine kinase inhibitor acquired resistance mechanism alternates between EGFR and ALK in a lung adenocarcinoma patient
por: Hu, Yijuan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_mr4hgr6jmaa0ib4i9aa17ltp93